| Start-up Australia is a specialist venture capital
company. We invest in innovative life science companies which have high growth prospects.
As an active investor, we work with inventors and company founders to create successful
companies using our investment. In most cases, Start-up Australia is the first investor in
a company and assists the company to reach the stage where it can commercialise its
product or technology internationally. The Start-up Australia team has extensive
experience in strategic planning and effective implementation required for success against
global competition.
Click here if you would
like to subscribe to our quarterly newsletter.
Latest News
Bionomics to undertake US clinical
trial on BNC210 in renal cell cancer.
Phase I clinical trial on Bionomics'
anti-anxiety drug BNC210 initiated.
Initial Phase I data on cancer drug
presented.
Anti-anxiety drug approved to enter
human clinical trials.
Start-up Australia completes $37.8
miilion exit.
Cephalon offer for Arana goes
unconditional.
Fondaparinux ANDA accepted by FDA for
review
Bionomics: New data on BNC105
presented to AACR.
Alchemia and SDP Technology enter
cancer drug collaboration.
Alchemia announces filing of
Abbreviated New Drug Application to FDA for fondaparinux.
Arana successfully completes Phase
II psoriasis clinical trial
Cephalon launches takeover offer for
Arana Therapeutics.
Bionomics options underwritten to
raise $4 million.
Anti-anxiety drug candidate BNC210
successfully completes safety studies.
Alchemia milestone payment from Dr Reddys
Bionomics options underwriting.
Arana commences international phase
II rheumatoid arthritis trial.
Arana completes second GSK project.
Arana commences Phase II rheumatoid
arthritis clinical trial.
FDA accepts Arana's anti-inflammatory
IND.
|
